Arnaud Drouin

Dr. Arnaud Drouin


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
ZHZhen Huang
Zhen Huang
DTDi Tian
Di Tian
YLYang Liu
Yang Liu
ZLZhen Lin
Zhen Lin
CLChristopher J. Lyon
Christopher J. Lyon
BNBo Ning
Bo Ning

1 June 2002 in Blood
Verified
Journal Article
Closed access
PDF file
TYTayebeh Youssefian
Tayebeh Youssefian
ADArnaud Drouin
Arnaud Drouin
JMJean-Marc Massé
Jean-Marc Massé
JGJosette Guichard
Josette Guichard
ECElisabeth M. Cramer
Elisabeth M. Cramer
Platelets can bind and phagocytose infectious microorganisms and so enable their transport for a prolonged time. To investigate the subcellular events of these interactions, platelets were incubated either with Staphylococcus aureus or with HIV and analyzed by electron microscopy (EM) and immuno-EM. HIV and bacteria internalization occurred exclusively within platelets showing morphological evidence of activation. Platelet activation enhanced the degree of bacterial internalization. Immunolabeling revealed that the engulfing vacuoles and the open canalicular system (OCS) were composed of distinct antigens. The engulfing vacuoles eventually became the site of prominent α-granule release. In platelets incubated with HIV, characteristic endocytic vacuoles were identified close to the plasma membrane, tightly surrounding 1 or 2 HIV particles. Virus particles were also located within the OCS. Immunogold labeling for the viral core protein p24 confirmed the presence of HIV within platelets. Finally, examination of platelets from a patient with acquired immunodeficiency syndrome and high viremia suggested that HIV endocytosis may also occur in vivo.

21 November 2021 in Viruses
Verified
Journal Article
Open access
PDF file
RBRodrigo Borrega
Rodrigo Borrega
DNDiana Nelson
Diana Nelson
AKAnatoliy P. Koval
Anatoliy P. Koval
NBNell G Bond
Nell G Bond
MHMegan L. Heinrich
Megan L. Heinrich
RGRobert Garry
Robert Garry
Many countries in sub-Saharan Africa have experienced lower COVID-19 caseloads and fewer deaths than countries in other regions worldwide. Under-reporting of cases and a younger population could partly account for these differences, but pre-existing immunity to coronaviruses is another potential factor. Blood samples from Sierra Leonean Lassa fever and Ebola survivors and their contacts collected before the first reported COVID-19 cases were assessed using enzyme-linked immunosorbent assays for the presence of antibodies binding to proteins of coronaviruses that infect humans. Results were compared to COVID-19 subjects and healthy blood donors from the United States. Prior to the pandemic, Sierra Leoneans had more frequent exposures than Americans to coronaviruses with epitopes that cross-react with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), SARS-CoV, and Middle Eastern respiratory syndrome coronavirus (MERS-CoV). The percentage of Sierra Leoneans with antibodies reacting to seasonal coronaviruses was also higher than for American blood donors. Serological responses to coronaviruses by Sierra Leoneans did not differ by age or sex. Approximately a quarter of Sierra Leonian pre-pandemic blood samples had neutralizing antibodies against SARS-CoV-2 pseudovirus, while about a third neutralized MERS-CoV pseudovirus. Prior exposures to coronaviruses that induce cross-protective immunity may contribute to reduced COVID-19 cases and deaths in Sierra Leone.

23 June 2021 in Viruses
Verified
Journal Article
Open access
PDF file
ADArnaud Drouin
Arnaud Drouin
MTMarc Theberge
Marc Theberge
SLSharon Y. Liu
Sharon Y. Liu
ASAllison R. Smither
Allison R. Smither
SFShelby M. Flaherty
Shelby M. Flaherty
Dahlene FuscoDahlene Fusco
Dahlene Fusco
A 59-year-old male with follicular lymphoma treated by anti-CD20-mediated B-cell depletion and ablative chemotherapy was hospitalized with a COVID-19 infection. Although the patient did not develop specific humoral immunity, he had a mild clinical course overall. The failure of all therapeutic options allowed infection to persist nearly 300 days with active accumulation of SARS-CoV-2 virus mutations. As a rescue therapy, an infusion of REGEN-COV (10933 and 10987) anti-spike monoclonal antibodies was performed 270 days from initial diagnosis. Due to partial clearance after the first dose (2.4 g), a consolidation dose (8 g) was infused six weeks later. Complete virus clearance could then be observed over the following month, after he was vaccinated with the Pfizer-BioNTech anti-COVID-19 vaccination. The successful management of this patient required prolonged enhanced quarantine, monitoring of virus mutations, pioneering clinical decisions based upon close consultation, and the coordination of multidisciplinary experts in virology, immunology, pharmacology, input from REGN, the FDA, the IRB, the health care team, the patient, and the patient’s family. Current decisions to take revolve around patient’s follicular lymphoma management, and monitoring for virus clearance persistence beyond disappearance of REGEN-COV monoclonal antibodies after anti-SARS-CoV-2 vaccination. Overall, specific guidelines for similar cases should be established.

2 February 2021 in Viruses
Verified
Journal Article
Open access
PDF file
Eric DumonteilEric Dumonteil
Eric Dumonteil
Dahlene FuscoDahlene Fusco
Dahlene Fusco
ADArnaud Drouin
Arnaud Drouin
CHClaudia Herrera
Claudia Herrera
Infections with SARS-CoV-2 can progress toward multiple clinical outcomes, and the identification of factors associated with disease severity would represent a major advance to guide care and improve prognosis. We tested for associations between SARS-CoV-2 genomic variants from an international cohort of 2508 patients and mortality rates. Findings were validated in a second cohort. Phylogenetic analysis of SARS-CoV-2 genome sequences revealed four well-resolved clades which had significantly different mortality rates, even after adjusting for patient demographic and geographic characteristics. We further identified ten single-nucleotide polymorphisms (SNPs) in the SARS-CoV-2 genome that were associated with patient mortality. Three SNPs remained associated with mortality in a generalized linear model (GLM) that also included patient age, sex, geographic region, and month of sample collection. Multiple SNPs were confirmed in the validation cohort. These SNPs represent targets to assess the mechanisms underlying COVID-19 disease severity and warrant straightforward validation in functional studies.

1 December 2001 in Experimental Cell Research
Verified
Journal Article
Closed access
ADArnaud Drouin
Arnaud Drouin
ASAlain Schmitt
Alain Schmitt
JMJean-Marc Massé
Jean-Marc Massé
ACAnne-Marie Cieutat
Anne-Marie Cieutat
SFSerge Fichelson
Serge Fichelson
ECElisabeth M. Cramer
Elisabeth M. Cramer